Filings & corporate actions
79 results filed
CSVNext results · Q2 FY27
Expected 10 Nov 2026 – 15 Nov 2026
Estimate: filed 41–46 days after quarter end, last 5 times
Dividend
₹2.50 per share · last 31 Aug 2026
2026
- 31 AugdividendDividend · ₹2.50 per share-1.4%
- 31 JulresultsResults · Q1 FY27 · consolidated and standalone-0.2%NSE
- 16 JulshareholdingShareholding · 30 Jun 2026-0.5%NSE
- 29 MayresultsResults · Q4 FY26 · consolidated and standalone-3.2%NSE
- 15 AprshareholdingShareholding · 31 Mar 2026+3.0%NSE
- 30 JanresultsResults · Q3 FY26 · consolidated and standalone-3.8%NSE
- 13 JanshareholdingShareholding · 31 Dec 2025-0.5%NSE
Reaction to results · all yearsrose on day 0 in 30 of 77 CSV
| Quarter | Filed | Day 0 | +5D | +20D | Rel vol |
|---|---|---|---|---|---|
| Q1 FY27 | 31 Jul 2026 | -0.2% | +0.8% | +11.0% | 2.4× |
| Q4 FY26 | 29 May 2026 | -3.2% | -4.3% | -3.1% | 2.6× |
| Q3 FY26 | 30 Jan 2026 | -3.8% | -4.0% | +6.0% | 0.8× |
| Q2 FY26 | 14 Nov 2025 | -1.4% | -2.8% | +4.7% | 8.2× |
| Q1 FY26 | 14 Aug 2025 | -3.5% | -4.3% | +1.6% | 1.9× |
| Q4 FY25 | 23 May 2025 | -2.1% | +5.4% | +18.6% | 3.5× |
| Q3 FY25 | 14 Feb 2025 | +3.8% | +0.2% | +12.4% | 5.2× |
| Q2 FY25 | 15 Nov 2024 | -3.1% | -0.8% | -1.3% | 2.3× |
| Q1 FY25 | 14 Aug 2024 | +5.0% | +13.1% | +17.6% | 6.4× |
| Q4 FY24 | 24 May 2024 | +8.1% | +13.5% | +17.1% | 12.1× |
| Q3 FY24 | 14 Feb 2024 | +1.6% | +14.5% | +17.6% | 5.2× |
| Q2 FY24 | 10 Nov 2023 | -1.9% | +0.9% | +2.5% | 0.6× |
| Q1 FY24 | 11 Aug 2023 | -0.5% | -5.3% | +1.6% | 0.7× |
| Q4 FY23 | 20 May 2023 | -2.9% | -4.8% | +2.6% | 2.7× |
| Q3 FY23 | 11 Feb 2023 | +5.5% | +8.0% | +3.8% | 9.3× |
| Q2 FY23 | 12 Nov 2022 | +4.1% | -0.5% | +2.8% | 3.2× |
| Q1 FY23 | 11 Aug 2022 | -0.1% | -5.0% | +1.1% | 1.7× |
| Q4 FY22 | 28 May 2022 | +2.9% | -1.3% | -3.0% | 2.2× |
| Q3 FY22 | 12 Feb 2022 | -2.3% | -6.9% | -9.3% | 0.9× |
| Q2 FY22 | 13 Nov 2021 | +2.3% | -1.4% | -1.1% | 2.6× |
| Q1 FY22 | 14 Aug 2021 | +1.1% | -7.4% | -4.9% | 2.1× |
| Q4 FY21 | 29 May 2021 | -2.5% | +1.4% | +9.8% | 0.9× |
| Q3 FY21 | 13 Feb 2021 | -2.7% | -6.9% | -5.4% | 1.3× |
| Q2 FY21 | 7 Nov 2020 | -5.9% | -4.8% | +4.6% | 3.1× |
| Q1 FY21 | 15 Aug 2020 | +1.0% | +2.6% | +1.5% | 2.6× |
| Q4 FY20 | 27 Jun 2020 | +0.2% | -8.3% | -8.8% | 1.1× |
| Q3 FY20 | 24 Feb 2020 | -2.9% | -6.2% | -36.3% | 1.7× |
| Q2 FY20 | 20 Nov 2019 | -2.7% | -4.1% | -2.4% | 0.7× |
| Q1 FY20 | 14 Aug 2019 | -6.0% | -4.2% | -3.5% | 4.7× |
| Q4 FY19 | 30 May 2019 | -1.6% | -3.7% | -20.4% | 2.1× |
| Q3 FY19 | 26 Feb 2019 | -0.7% | +1.8% | +9.7% | 1.1× |
| Q2 FY19 | 26 Nov 2018 | +0.5% | -2.6% | +6.1% | 1.4× |
| Q1 FY19 | 28 Aug 2018 | -1.4% | +0.5% | -1.3% | 0.8× |
| Q4 FY18 | 29 Jun 2018 | +1.8% | +1.8% | 0.0% | 0.5× |
| Q3 FY18 | 14 Feb 2018 | -0.2% | -1.3% | +3.0% | 0.8× |
| Q2 FY18 | 7 Nov 2017 | -3.3% | -6.4% | -12.5% | 1.3× |
| Q1 FY18 | 2 Aug 2017 | -0.1% | -12.9% | -14.3% | 1.1× |
| Q4 FY17 | 15 May 2017 | -0.2% | -9.0% | -11.9% | 2.3× |
| Q3 FY17 | 7 Feb 2017 | +0.1% | -1.3% | -6.8% | 0.8× |
| Q2 FY17 | 7 Nov 2016 | -0.1% | -3.0% | -2.9% | 1.1× |
| Q1 FY17 | 23 Sept 2016 | +1.7% | -0.7% | +0.4% | 2.2× |
| Q4 FY16 | 16 May 2016 | +0.6% | -1.2% | -11.3% | 0.6× |
| Q3 FY16 | 1 Feb 2016 | +3.2% | -2.7% | -4.6% | 1.3× |
| Q2 FY16 | 2 Nov 2015 | -0.8% | -2.9% | -1.2% | 0.6× |
| Q1 FY16 | 30 Jul 2015 | +5.8% | +5.4% | +22.8% | 1.7× |
| Q4 FY15 | 29 May 2015 | -1.1% | -2.2% | +11.3% | 1.7× |
| Q3 FY15 | 19 Feb 2015 | -1.1% | -1.3% | +9.1% | 0.4× |
| Q2 FY15 | 4 Nov 2014 | +5.2% | +5.8% | +11.4% | 1.9× |
| Q1 FY15 | 24 Jul 2014 | +6.6% | +12.3% | +21.7% | 4.3× |
| Q4 FY14 | 8 May 2014 | -2.2% | -9.1% | -5.6% | 1.1× |
| Q3 FY14 | 24 Jan 2014 | +5.0% | +8.7% | +6.9% | 5.1× |
| Q2 FY14 | 5 Nov 2013 | -1.5% | -6.0% | +0.1% | 1.3× |
| Q1 FY14 | 2 Aug 2013 | -2.6% | -4.1% | -10.7% | 4.9× |
| Q4 FY13 | 7 May 2013 | +1.0% | +5.2% | +14.6% | 2.1× |
| Q3 FY13 | 29 Jan 2013 | -1.0% | +0.1% | +1.1% | 5.6× |
| Q2 FY13 | 30 Oct 2012 | +8.6% | +9.4% | +10.0% | 8.8× |
| Q1 FY13 | 4 Aug 2012 | -0.3% | +1.6% | +2.8% | 2.4× |
| Q4 FY12 | 9 May 2012 | +3.3% | +5.6% | +8.7% | 2.2× |
| Q3 FY12 | 31 Jan 2012 | -5.4% | -5.1% | -1.0% | 9.5× |
| Q2 FY12 | 9 Nov 2011 | -1.1% | -1.0% | -5.4% | 2.3× |
| Q1 FY12 | 26 Jul 2011 | +2.6% | +0.4% | -3.1% | 7.0× |
| Q3 FY11 | 1 Feb 2011 | -2.2% | -5.4% | -6.3% | 0.7× |
| Q2 FY11 | 27 Oct 2010 | +3.9% | +17.7% | +13.8% | 3.1× |
| Q1 FY11 | 27 Jul 2010 | 0.0% | -5.6% | +3.4% | 4.5× |
| Q4 FY10 | 28 May 2010 | +0.4% | -4.4% | +1.3% | 1.4× |
| Q3 FY10 | 29 Jan 2010 | +1.9% | +4.9% | +6.0% | 0.4× |
| Q2 FY10 | 29 Oct 2009 | -1.6% | +3.7% | +9.6% | 0.8× |
| Q1 FY10 | 27 Jul 2009 | -2.0% | -5.9% | -18.0% | 1.2× |
| Q4 FY09 | 27 Jun 2009 | -1.3% | -1.3% | +13.3% | 1.0× |
| Q3 FY09 | 27 Jan 2009 | -7.6% | -36.0% | -31.6% | 2.4× |
| Q2 FY09 | 27 Oct 2008 | -20.0% | -5.6% | +0.6% | 1.1× |
| Q1 FY09 | 28 Jul 2008 | -0.9% | -5.3% | -3.1% | 1.6× |
| Q4 FY08 | 28 Apr 2008 | +4.3% | +7.3% | +10.7% | 4.3× |
| Q3 FY08 | 21 Jan 2008 | -14.0% | -5.5% | -9.4% | 1.6× |
| Q2 FY08 | 31 Oct 2007 | +3.7% | +2.5% | -5.3% | 3.3× |
| Q1 FY08 | 30 Jul 2007 | -0.6% | -5.0% | -2.7% | 1.0× |
| Q4 FY07 | 25 Apr 2007 | -1.2% | -4.8% | +1.9% | 2.6× |
| Average | -0.4% | -1.2% | +0.9% | ||
Close-to-close from the session before the filing could trade. Day 0 is the first session after it.
Growth · Q1 FY27
CSVRevenue YoY+23.1%
Profit YoY+927.9%
Interest cost YoY-9.4%
Revenue QoQ+6.6%
Profit QoQ+60.2%
| CAGR | 2Y | 3Y | 4Y | 5Y | 6Y | 7Y |
|---|---|---|---|---|---|---|
| Revenue | +21.5% | +9.2% | +10.0% | +8.9% | +8.9% | +8.5% |
| Profit | — | +74.3% | +18.9% | +11.9% | +11.8% | +12.2% |
Key data
CSVOpen2,312.20
Day range2,277.30 – 2,320.00
52-week range1,792.60 – 2,537.60
From 52w high-8.9%
RSI (14)42.3
ATR (14)66.73
Volume4.94L
Avg volume (20D)5.80L
Rel volume0.85×
Volatility (1Y)27.0%
Turnover₹114.1Cr
SMA 50 / 2002,358.07 / 2,203.81
Delivery percentage
Latest · 6 Oct 202656.1%
20-day avg53.8%
1-year avg47.2%
Percentile (own history)92nd
Range4.3–80.0%
Sessions1,731
Over the last 20 sessions GLENMARK settled 53.8% of its traded quantity, which is above average for an NSE equity. Its one-year average is 47.2%, so recent sessions are running 6.7 points higher than usual. The latest session ranks higher than 92% of the 1,731 sessions on record for it.
What delivery percentage measuresScan the whole market on delivery
IndustryPharmaceuticals
Performance returns
CSV| 1D | 1W | 1M | 3M | 6M | 1Y | |
|---|---|---|---|---|---|---|
| Price | +0.70% | -0.63% | -6.02% | +2.04% | +10.48% | +17.21% |
Valuation
CSVMarket cap₹65,222 Cr
P/E (TTM)36.3
EPS (TTM)63.70
Shares outstanding28.22Cr
Listed7 Feb 2000
Ownership
CSVPromoter—
Promoter Δ QoQ—
Public—
FII—
DII—
Pledged—
Quarterly results · consolidated
CSV| Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | |
|---|---|---|---|---|
| Revenue (₹ Cr) | 6,046.9 | 3,900.6 | 3,770.6 | 4,018.5 |
| YoY chg | +76.1% | +15.1% | +15.8% | +23.1% |
| Net profit (₹ Cr) | 610.4 | 403.2 | 301.3 | 482.8 |
| YoY chg | +72.2% | +15.9% | +6773.2% | +927.9% |
| Net margin | 10.1% | 10.3% | 8.0% | 12.0% |
| EPS | 21.62 | 14.28 | 10.68 | 17.11 |
Shareholding over time
CSVBy quarter
30 Jun 2026 · promoter 46.65% · public 53.35%2020-092026-06
- Promoter
- Public and others
- Promoter
- 46.65%
- Public
- 53.35%
- Promoter change
- 0.00 pp
- Filed
- 16 Jul 2026
- FII
- 20.89%
- DII
- 18.60%
- Promoter pledged
- 0.00%
Promoter and public shares of total equity, from the pattern filed each quarter. Institutional and pledge figures come from a separate filing stage whose backfill is still running, so they are absent for almost every instrument rather than zero.
Financials · quarterly statement
CSV₹ crore, as filed
| Q2 FY24 | Q3 FY24 | Q4 FY24A | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25A | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26A | Q1 FY27 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 3,207.4 | 2,506.7 | 3,063.0 | 3,244.2 | 3,433.8 | 3,387.6 | 3,256.2 | 3,264.4 | 6,046.9 | 3,900.6 | 3,770.6 | 4,018.5 | |
| Other income | 1.7 | 45.4 | 773.2 | 31.5 | 39.4 | 31.1 | 11.7 | 26.4 | 200.6 | 44.5 | 189.1 | 65.8 | |
| Total income | 3,209.1 | 2,552.1 | 3,836.1 | 3,275.7 | 3,473.2 | 3,418.7 | 3,267.9 | 3,290.9 | 6,247.5 | 3,945.1 | 3,959.7 | 4,084.2 | |
| Total expenses | 3,008.0 | 2,996.8 | 2,858.5 | 2,813.3 | 3,000.6 | 2,962.4 | 2,887.1 | 2,872.1 | 3,895.0 | 3,226.7 | 3,198.5 | 3,440.9 | |
| └ Finance costs | 121.5 | 134.3 | 148.6 | 39.6 | 48.5 | 52.3 | 66.7 | 58.2 | 66.5 | 41.4 | 42.6 | 54.0 | |
| └ Depreciation | 141.5 | 147.1 | 151.3 | 117.8 | 120.3 | 122.7 | 125.2 | 129.9 | 141.2 | 154.4 | 147.9 | 173.2 | |
| Profit before tax | (124.4) | (521.4) | 530.8 | 462.3 | 472.6 | 456.3 | 8.0 | 95.6 | 967.4 | 534.0 | 387.8 | 643.4 | |
| Tax expense | 55.9 | (71.8) | 1,769.5 | 122.1 | 118.1 | 108.3 | 3.6 | 48.6 | 357.0 | 130.8 | 86.4 | 160.6 | |
| Net profit | (63.6) | (330.8) | (1,214.3) | 340.2 | 354.5 | 348.0 | 4.4 | 47.0 | 610.4 | 403.2 | 301.3 | 482.8 | |
| EPS | -2.90 | -12.45 | -43.18 | 12.06 | 12.55 | 12.33 | 0.16 | 1.66 | 21.63 | 14.29 | 10.68 | 17.11 | |
| Net margin | -1.98% | -13.20% | -39.64% | 10.49% | 10.32% | 10.27% | 0.13% | 1.44% | 10.10% | 10.34% | 7.99% | 12.02% | |
| PBT margin | -3.88% | -20.80% | 17.33% | 14.25% | 13.76% | 13.47% | 0.24% | 2.93% | 16.00% | 13.69% | 10.28% | 16.01% | |
| Tax rate | — | — | 333.34% | 26.41% | 24.99% | 23.73% | 45.02% | 50.85% | 36.90% | 24.49% | 22.29% | 24.96% |
A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. A quarterly filing carries a profit and loss only — there is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure here. Latest filed 31 Jul 2026.
GLENMARK at a glance
- GLENMARK closed at ₹2,311 on 6 Oct 2026, +0.70% on the day, +17.2% over one year, 8.9% below its 52-week high of ₹2,537.6.
- Delivery was 56.1% of traded quantity on 6 Oct 2026, the 92nd percentile of its own 1,731 sessions with a reading (20-session average 53.8%, 1-year average 47.2%).
- Market capitalisation is ₹65,222 crore at a trailing P/E of 36.3 (trailing EPS ₹63.7).
- Q1 FY27 results (consolidated, filed 31 Jul 2026): revenue ₹4,018 crore (+23.1% year on year), net profit ₹483 crore (+927.9%); the price moved -0.2% on the first session after.
- Promoters held 46.65% at 30 Jun 2026, unchanged on the previous filing.
- Q2 FY27 results are expected between 10 Nov 2026 and 15 Nov 2026, going by past filing dates — an estimate, not an announcement.
About
CSVMacro sectorHealthcare
Basic industryPharmaceuticals
ISININE935A01035
SeriesEQ
Listed7 Feb 2000
History from10 Feb 2000
Sessions6,621
Turnover rank#226
Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 6 Oct 2026.
More in Pharmaceuticals & Biotechnology
CSV- DIVISLABDivi's Laboratories Limited9,550.00+3.85%
- LAURUSLABSLaurus Labs Limited2,050.00+3.99%
- SUNPHARMASun Pharmaceutical Industries Limited1,804.10+1.37%
- WOCKPHARMAWockhardt Limited2,176.40+5.47%
- DRREDDYDr. Reddy's Laboratories Limited1,208.00+0.42%
- MOREPENLABMorepen Laboratories Limited143.96+6.41%
- ZYDUSLIFEZydus Lifesciences Limited1,159.50+1.80%
- SYMBIOTECSYMBIOTEC1,149.50-1.73%
- TORNTPHARMTorrent Pharmaceuticals Limited4,772.000.00%
- GLANDGland Pharma Limited3,006.10+3.25%
- LUPINLupin Limited2,029.30+0.91%
- AUROPHARMAAurobindo Pharma Limited1,692.80+1.07%
All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE